T Helper Cell–Mediated In Vitro Responses of Recently and Remotely Infected Subjects to a Candidate Recombinant Vaccine for Human Parvovirus B19

T cell proliferation to human parvovirus B19 antigen was measured in 6 patients with recent B19 infection (1 with pneumonia and pleuritis), 1 patient with symptoms persisting >180 days after onset, 18 nonsymptomatic subjects with remote B19 immunity, and 12 B19-seronegative control subjects. Reco...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2001-03, Vol.183 (5), p.805-809
Main Authors: Franssila, Rauli, Hokynar, Kati, Hedman, Klaus
Format: Article
Language:English
Subjects:
Acute-Phase Reaction
Adult
Antigens
Antigens, Viral - immunology
Arthralgia
B-Lymphocytes - immunology
Biological and medical sciences
Capsid
Capsid - genetics
Capsid - immunology
Cells, Cultured
Concise Communications
Exanthema
Female
Fundamental and applied biological sciences. Psychology
human parvovirus B19
Human viral diseases
Humans
Infections
Infectious diseases
Male
Medical sciences
Microbiology
Middle Aged
Parvoviridae Infections - prevention & control
Parvovirus
Parvovirus B19
Parvovirus B19, Human - genetics
Parvovirus B19, Human - immunology
Reactivity
T lymphocytes
T-Lymphocytes, Helper-Inducer - immunology
Transponders
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Synthetic - immunology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Vaccines - immunology
Virology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T cell proliferation to human parvovirus B19 antigen was measured in 6 patients with recent B19 infection (1 with pneumonia and pleuritis), 1 patient with symptoms persisting >180 days after onset, 18 nonsymptomatic subjects with remote B19 immunity, and 12 B19-seronegative control subjects. Recombinantly expressed virus-like particles (VP1/2 capsids), a candidate B19 vaccine, were used as antigen. Virus-specific T helper cell proliferation was detectable in all the recently infected patients and in most (17/18) of the remotely infected subjects but not in the seronegative control subjects. The B19-specific T cell responses, in general, were most vigorous among the recently infected patients. However, such strong B19-specific proliferation was not confined within the acute phase, as 28% (5/18) of the remotely infected healthy individuals had B19-specific reactivity persisting at acute-phase levels, apparently for years or decades. These data indicate that B cells recognizing the VP1/2 capsids receive class II–restricted help from CD4+ T lymphocytes
ISSN:0022-1899
1537-6613
DOI:10.1086/318819